Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.04 is 31% above its 3-year average of 0.03, near the high end of its 3-year range (0.00–0.04).
As of the fiscal period ended Tuesday, June 30, 2026. 21.85% above its 12-month average of 0.03.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.04.
DEBT TO EQUITY RATIO
0.04
DEBT TO EQUITY RATIO AVG TTM
0.03
DEBT TO EQUITY RATIO AVG 3Y
0.03
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+21.85%
CURRENT VS 3Y AVG
+31.44%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12
median of 639 covered companies
CURRENT VS SECTOR MEDIAN
-70.07%
vs the sector median at left
Market Cap
$6.01B
Debt to Equity Ratio
1.17
TTM Avg
0.23
3Y Avg
0.15
5Y Avg
0.27
Market Cap
$5.94B
Debt to Equity Ratio
0.06
TTM Avg
0.08
3Y Avg
0.11
5Y Avg
0.11
Market Cap
$5.82B
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$6.51B
Debt to Equity Ratio
0.48
TTM Avg
0.57
3Y Avg
0.80
5Y Avg
0.68
Market Cap
$6.54B
Debt to Equity Ratio
84.54
TTM Avg
74.29
3Y Avg
41.61
5Y Avg
30.23
Market Cap
$5.53B
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $6.06B | 0.04 | 0.03 | 0.03 | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.01B | 1.17 | 0.23 | 0.15 | 0.27 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.94B | 0.06 | 0.08 | 0.11 | 0.11 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.82B | 0.01 | 0.02 | 0.02 | 0.02 |
| CG Oncology Inc. (CGON)vs › | $5.79B | 0.01 | 0.01 | 0.04 | 0.11 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 0.48 | 0.57 | 0.80 | 0.68 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.54B | 84.54 | 74.29 | 41.61 | 30.23 |
| RadNet, Inc. (RDNT)vs › | $5.53B | 1.99 | 1.81 | 2.63 | 3.97 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.53B | 0.02 | 0.02 | 0.01 | 0.01 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.59B | 4.77 | 1.04 | 0.53 | 0.36 |
Debt/Equity
0.04
Current Ratio
10.95
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.04 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | 0.04 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.03 |
| 2025-03-31 | 0.03 |
| 2024-12-31 | 0.03 |
| 2024-09-30 | 0.03 |
| 2024-06-30 | 0.03 |
| 2024-03-31 | 0.02 |
| 2023-12-31 | 0.02 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-04-02 | 0.00 |
